BIONTECH SE SPON. ADRS 1
Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST
BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential
A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.
Read
Commented by Nico Popp on June 14th, 2022 | 12:26 CEST
Unheeded crisis signals! What is next: BioNTech, Lufthansa, Triumph Gold
There are always comeback stocks on the stock market. The airports are full of travellers who are being drawn to distant countries. So the tourism industry, and airlines too, could almost strap themselves in for a comeback. If only it weren't for the new BA.5 virus variant, which has infected large parts of the population in Portugal within a very short time. It seems investors have to choose between travel stocks and pandemic stocks when looking for comeback stocks - or is there a laughing third party?
Read
Commented by Armin Schulz on June 10th, 2022 | 11:48 CEST
BioNTech, NervGen Pharma, Valneva - Which stock will make the breakthrough in incurable diseases?
The number of cancer patients increases every year, and only if the disease is detected at an early stage might a cure still be possible. With other diseases such as multiple sclerosis or Alzheimer's, there is no chance of a cure at all. The deterioration progresses slowly and unstoppably. COVID-19 has also shown us how vulnerable humanity is to a virus. But many biotech companies have taken up the fight against these diseases. Any drug that can stop the progression of these diseases would help those affected. Many biotech stocks have corrected significantly recently. Today we take a look at three companies and their existing potential against incurable diseases.
Read
Commented by Carsten Mainitz on June 7th, 2022 | 11:32 CEST
XPhyto, BioNTech, MorphoSys - The next price wave is coming!
In recent years, Corona has been the most urgent topic that has moved the world and the stock markets. Health care is and remains a megatrend. It is in the nature of things that the focus changes over time. Innovative approaches or forms of drug delivery, on the other hand, remain perennial favorites. There is also a lot of progress in research against cancer. These companies will play a major role in the future.
Read
Commented by Fabian Lorenz on June 1st, 2022 | 13:44 CEST
Rain of money for BioNTech shareholders: What are Nordex and Meta Materials doing?
BioNTech shareholders are in for a windfall. A dividend of EUR 2 per share is to be approved at today's Annual General Meeting. Also on the agenda is a share buyback program with a volume of up to USD 1.5 billion. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. Meta Materials shareholders are still a long way from a dividend. But the hot stock has announced exciting details about its fight against stroke. At Nordex, by contrast, supply chain problems, plant closures and cyberattacks dominate the headlines. But analysts see the light at the end of the tunnel - and rightly so?
Read
Commented by André Will-Laudien on May 31st, 2022 | 12:03 CEST
Watch out: BioNTech, NervGen, MorphoSys, Valneva: Biotech shares in check!
The initial sell-off in biotech stocks seems to have been digested. With last week's NASDAQ turn, spring air is now moving through the stock markets again. That is because many investors realize that, in the face of a multitude of new diseases, a major research effort is needed to protect humanity from the burgeoning dangers. Financing via the stock market was correspondingly easy for the biotech giants during the last pandemic because investors sensed big profits in the event of success. This picture is likely to repeat itself in the next movement. Where are the current opportunities in the biopharma sector?
Read
Commented by Juliane Zielonka on May 27th, 2022 | 12:39 CEST
BioNTech, XPhyto Therapeutics, Snap Inc. - Tech falls, biotech gains
The bearish market continues to slide. Tech companies like Snap Inc. saw share price declines of 31%. An alternative to high growth stocks are life science accelerators like XPhyto Therapeutics Corp. They are betting on the right partners and funds to bring biotech products to market faster than usual. While still with emergency approval, BioNTech is at the starting line for a Corona vaccine. Both German STIKO and partner Pfizer in the US are now targeting children for a COVID-19 vaccine.
Read
Commented by Armin Schulz on May 26th, 2022 | 11:22 CEST
BioNTech, Meta Materials, Plug Power - Future stocks for tomorrow's profits
Shares that focus on future trends harbor both risks and opportunities. If a breakthrough succeeds in a new area, high returns beckon. The business areas can be very different, but they have one thing in common: they will revolutionize people's lives in the future. Examples from the past include computers and cell phones, which ultimately permeated society. Today, we look at three companies that could significantly impact the future.
Read
Commented by Stefan Feulner on May 23rd, 2022 | 13:01 CEST
BioNTech, Monkeypox, Defence Therapeutics, Valneva - Is the next threat coming after Corona?
The Corona pandemic is not over yet, but we should already prepare for future viruses. The next pandemic will come. When it will come is uncertain, and so is which pathogen will we have to deal with. Monkeypox is now spreading globally, and there are already the first cases in Germany. We find out what is known so far, where the dangers lie and what opportunities there are for the biotechnology sector from Dr Moutih Rafei, a renowned pharmacologist and head of research and development at the innovative company Defence Therapeutics Inc.
Read
Commented by Fabian Lorenz on May 19th, 2022 | 13:31 CEST
Booster for the BioNTech share: BASF and Defense Metals with momentum?
The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.
Read